InVitria was founded with a mission to eliminate the need for blood-derived raw materials in biomanufacturing and drug formulation, primarily targeting the growing demand for human and animal serum in emerging advanced treatments like cell therapies, gene therapies, and the new generation of vaccines.
Colorado BioScience Association President and CEO, Elyse Blazevich, asked Scott Deeter, CEO of Invitria, CBSA’s Key Questions for Life Sciences Innovators.
Q: Tell us about your company or organization.
A: InVitria’s technology has brought to market the first and only recombinant albumin approved by FDA and EMA as an excipient in biologics. In contrast, our recombinant transferrin is currently used in market-leading cancer therapies. InVitria’s other single component and cell culture products are also currently included in multiple clinical material manufacturing processes across the…
Click here to view original post
